Ventyx Biosciences, Inc.

NASDAQ•VTYX

CEO: Dr. Sheila K. Gujrathi M.D.

セクター: Healthcare

業種: Biotechnology

上場日: 2021-10-21

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

連絡先情報

12790 El Camino Real, Suite 200, San Diego, CA, 92130, United States

760-593-4832

ventyxbio.com

時価総額

$1.00B

PER (TTM)

-9.4

17.9

配当利回り

52週高値

$25.00

52週安値

$0.78

52週レンジ

55%

順位59Top 87.6%

2.2

F-Score

改良版 Piotroski 分析

6年ファンダメンタル

弱い • 2.2 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2020-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.32-36.00%

直近4四半期の推移

フリーCF

-$17.56M-50.49%

直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Net Loss Significantly Reduced Nine-month net loss narrowed to $77.3M USD, improving from $105.8M USD loss last period, reflecting better operational control.

R&D Spending Decreased Total R&D expenses for nine months fell $29.3M USD to $62.9M USD, primarily due to closeout of older development programs.

Operating Cash Burn Improved Cash used in operating activities decreased to $64.5M USD over nine months, showing better cash management compared to prior year.

VTX3232 Clinical Data Positive Reported positive topline results for VTX3232 in early-stage Parkinson's Phase 2a trial in June 2025 and obesity trial in October 2025.

リスク要因

Future Financing Requirements High Substantial additional capital needed for development; failure to secure funding could delay or terminate critical product development efforts.

Clinical Trial Data Uncertainty Preliminary data may change materially upon audit; high attrition rate in clinical development remains a significant inherent risk factor.

VTX958 Internal Resource Reduction Will not commit significant internal resources to VTX958 development following Crohn's Phase 2 results, refining future strategy.

Stock Price Volatility Expected Stock price highly volatile based on clinical trial announcements and general market conditions; potential for significant investor loss.

見通し

VTX2735 Phase 2 Results Due Anticipate interim topline results for VTX2735 Phase 2 trial in recurrent pericarditis during the fourth quarter of 2025.

Tamuzimod Partnering Exploration Intend to identify a partner or secure non-dilutive financing to support the pivotal Phase 3 program for tamuzimod in UC.

Cash Sufficient Twelve Months Current cash, equivalents, and marketable securities estimated sufficient to fund obligations for at least twelve months from report date.

Continue IP Protection Efforts Will continue efforts to obtain and enforce patent protection for product candidates against potential third-party infringement and maintain competitive edge.

同業比較

売上高 (TTM)

RIGL

$294.28M

+64.1%

RGNX

$170.44M

+104.5%

GOSS

$44.05M

-58.2%

粗利益率 (最新四半期)

GOSS

100.0%

+0.0pp

ABSI

100.0%

+197.2pp

VYGR

93.2%

+0.0pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
CRVS	$1.28B	-79.2	-23.3%	1.3%
MLTX	$1.23B	-4.9	-67.1%	17.8%
OLMA	$1.16B	-8.4	-41.5%	1.3%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし